Click on Target: Developing a Safe Drug with Enhanced Therapeutic Potential for Prostate Cancer Treatment
Prostate cancer is the most common malignancy in men and the fifth cause of cancer-related death globally. Currently used imaging modalities and therapeutic options are still limited; especially for the detection and treatment of (oligo)metastatic disease, improvements are needed for more accurate detection and dedicated, precise treatment with a low toxicity profile. The aim of this preclinical project is to develop and evaluate a pretargeting strategy based on click-chemistry for safe and effective gastrin releasing peptide receptor (GRPR)-targeted radionuclide therapy.
This study is an essential step towards safe and effective use of GRPR-targeting radiopeptides for prostate cancer therapy, which will ultimately contribute to more cure and improved quality of life.
More detailed information
Dr. Simone Dalm
Role Erasmus MC:
KWF Kankerbestrijding /
Young Investigator Grant